Novo Nordisk and Heartseed first partnered in 2021 to develop an investigational cell therapy for heart failure.

M&A headlined for a second straight week as Genmab acquired Merus for $8 billion; Pfizer strikes most-favored-nation deal ...

A new analysis from SRS Acquiom puts into perspective the headline values seen when a company announces a backloaded M&A deal ...

J&J still holds the top deal of the year by value with its $14.6 billion buy of Intra-Cellular in January, but the next four ...

The two most historically deal-conservative Big Pharmas have the most money to play with for a major M&A transaction, ...

Talks between pharma and successive U.K. governments have failed to deliver the market access terms that the industry wants, ...

Without naming Aurinia Pharmaceuticals, the CDER director in a now-deleted LinkedIn post claimed that for lupus nephritis, ...

MET-097i’s mid-stage performance “bodes well” for Pfizer’s proposed buyout of Metsera, according to BMO Capital Markets, a ...

Despite tolerability concerns, nomlabofusp's overall efficacy represents a “large win” for Larimar, according to analysts at ...

Pfizer CEO Albert Bourla directly credited the threat of tariffs with leading to the deal, in which the company will offer ...

The agency estimates that about 86% of staff can remain in the event that funding stops, but new drug applications cannot be ...

Already approved in Japan, China and other Asian countries, Crystalys’ dotinurad works to lower serum uric acid levels.